Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2000-02-29
2001-05-01
Myers, Carla J. (Department: 1656)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S024310, C536S024330
Reexamination Certificate
active
06225069
ABSTRACT:
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD), the most common cause of dementia, is estimated to affect 5% of those over 65 years of age and 40% of those over 80 years of age, or a total of approximately 20 million people worldwide. The neuropathological characteristics of AD include: &bgr;-amyloid plaques that are diagnostic when associated with dystrophic neurites; neurofibrillary tangles; loss of neurons and synapses; and proliferation of glial cells. The last few years have seen substantial progress in unravelling the genetic influences in AD. A small proportion of AD cases are inherited as an autosomal dominant trait and are attributable to point mutations in genes encoding &bgr;-amyloid precursor protein (&bgr;APP),
1
presenilin 1,
2
or presenilin 2.
3
A major genetic risk factor for the much more common sporadic AD is possession of the apolipoprotein E (APOE) e4 allele.
4
However possession of APOE e4 is neither necessary nor sufficient for the development of AD, leaving scope for other potential genetic or environmental influences.
Interleukin-1 (IL-1) is a potent pro-inflammatory cytokine that is markedly overexpressed in Alzheimer brain, predominantly in microglia,
5
suggesting a role for inflammatory processes in AD pathogenesis.
6
This idea has received support from epidemiological studies showing that use of anti-inflammatory agents, in particular non-steroidal anti-inflammatory drugs, is associated with delayed onset or slowed progression of disease.
7
IL-1 has two structurally distinct forms, IL-1a and IL-1&bgr;, encoded by separate genes (IL-1 and IL-1B, respectively) located in a cluster on the long arm of chromosome 2 that also includes the IL-1 receptor antagonist gene.
8
Common polymorphisms have been described in both genes and there is evidence that they have functional significance. A polymorphism of the IL-1B gene (+3953), for instance, introduces a Taq1 restriction site resulting in two alleles, designated allele 1 and allele 2.
9
Homozygosity for allele 2 of IL-1B is associated with a fourfold increase in production of IL-1&bgr; compared to homozygosity for allele 1.
9
A polymorphism in the 5′ regulatory region of the IL-1 gene (a C to T transition at position −889 relative to the start site of transcription) again results in two alleles, also designated allele 1 and allele 2.
10
Both of these IL-1 polymorphisms have been associated with inflammatory diseases. For instance, IL-1 allele 2 has been associated with juvenile rheumatoid arthritis.
10
Genetic testing is now possible (see U.S. Pat. Nos. 4,582,788, 5,110,920 and 5,686,246) for diseases associated with or caused by one to two genes, once the genes are identified, to determine the risk of a person carrying a given gene for the disease (see for example U.S. Pat. Nos. 4,801,531, 4,666,828, 5,268,267 and 5,686,246). These patents are hereby incorporated by reference into this disclosure.
Many altered physiological functions induce or are caused by inflammatory and other immune mechanisms (see U.S. Pat. No. 5,328,829, column 1, for a review). Due to the commonality of the immune response in almost all disease states, research on inflammatory markers as genetic markers has had very limited success at differentiating predisposition to diseases. U.S. Pat. No. 5,686,246, is a notable exception, in that the inventors correlated IL-1a and IL-1b mutations with the susceptibility to severe periodontal disease.
Association of a single cytokine polymorphism and disease states have been found as, for example, in Systemic Lupus Erythematosus, Ulcerative Colitis and Juvenile rheumatoid arthritis (Mansfield et al., 1994; Verjans et al., 1992; Blakemore et al., 1994; McGuire et al., 1994; McDowell et al., 1995).
Therefore, it was an objective of the present invention to determine if genetic factors that are associated with inflammatory and other immune responses correlate with Alzheimer's disease. If so, it would be useful to identify the genetic factors and thereby identify persons who are susceptible to Alzheimer's disease for the purpose of providing prophylactic treatment.
SUMMARY OF THE INVENTION
It is therefore an object of the present invention to provide methods useful to predict increased risk of Alzheimer's disease development. The method includes investigation of the IL-1A and/or IL-1B banding pattern on a gel, or similar investigation of the genotype at the IL-1A and/or IL-1B locus.
It is a further object to provide kits for determining if a person has a genetic predisposition for Alzheimer's disease development. The kits comprise means for investigating the genotype of an individual at the IL-1A and/or IL-1B locus, and, optionally, other convenient tools which furthers the investigation.
REFERENCES:
patent: 4582788 (1986-04-01), Erlich
patent: 4666828 (1987-05-01), Gusella
patent: 4801531 (1989-01-01), Frossard
patent: 5110920 (1992-05-01), Erlich
patent: 5268267 (1993-12-01), Smith
patent: 5328829 (1994-07-01), Stashenko
patent: 5686246 (1997-11-01), Kornman et al.
Barger SW, et al., Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E.Nature1997;388:878-881.
Blakemore, AIF, et al., Interleukin-1 Receptor Antagonist Gene Polymorphism as a Disease Severity Factor in Systemic Lupus Erythematosus.Arthritis&Rheumatism 1994;37:9:1380-1385.
Breitner JCS, et al., Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a con-twin control study.Neurology1994;44:227-232.
Buxbaum JD, et al., Cholineric agonists and interleukin 1 regulate processing and secretion of the Alzheimer bata/A4 amyloid protein precursor.Proc Natl Acad Sci USA1992;89:10075-10078.
Forloni, G., et al., Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: Modulation by interleukin-1.Mol Brain Res1992;16:128-134.
Goate A, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.Nature1991;349:704-706.
Griffin WS, et al., Brain interleukin 1 and S-200 immunoreactivity are elevated in Down syndrome and Alzheimer disease.Proc Natl Acad Sci USA1989;86:7611-7615.
Griffin WS, et al., Glial-Neuronal Interactions in Alzhemier's Disease: The Potential Role of a Cytokine Cycle in Disease Progression.Brain Pathol1998; 8:65-72.
Griffin WS, et al., Microglial interleukin-1&agr; expression in human head injury: correlations with neuronal and neuritic &bgr;-amyloid precursor protein expression.Neurosci Lett1994; 176:133-136.
Mansfield JC, et al., Novel Genetic Association between Ulcerative Colitis and the Antiinflammatory Cytokine Interleukin-1 Receptor Antagonist.Gastroenterology1994;106-:637-642.
McDonell, TL, et al., A genetic association between juvenile rheumatiod arthritis and a novel interleukin-1&agr; polymorphism.Arthritis&Rheumatism1995;35-221-228.
McGuire, William, et al., Variation in the TNF-&agr; promoter region associated with susceptibility to cerebral malaria.Nature1994;371:508-511.
Mortimore JA, et al., Head trauma as a risk factor for Alzheimer's disease: a collaborative reanalysis of case-control studies.Eurodem Risk Factors Research Group. Int J. Epidemiol1991;20(suppl):S28-35.
Nicklin MJH, et al., A Physical Map of the Region Encompassing the Human Interleukin-1&agr;, Interleukin-1&bgr;, and Interleukin-1 Receptor Antagonist Genes,Genomics1994;19:382-384.
Nicoll JA, et al., Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid &bgr;-protein following head injury.Nat Med1995;1:2:135-137.
Pociot F, et al., A TagI polymorphism in the human interleukin-1&bgr; (IL-1&bgr;) gene correlates with IL-1&bgr; secretion in vitro.Eur J Clin Invest1992;22:396-402.
Rogaev EI, et al., Familial Alzhemier's disease in kindreds with messense mutuations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene.Nature1995;376:775-778.
Rogers JT, et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by Interleukin-1 through
Griffin W. Sue T.
Nicoll James A. R.
Kennedy Pat Winston
Kilpatrick & Stockton LLP
Myers Carla J.
Spiegler Alexander H.
The Board of Trustees of the University of Arkansas
LandOfFree
Methods to identify genetic predisposition to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods to identify genetic predisposition to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to identify genetic predisposition to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2569471